{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T06:20:24Z","timestamp":1788848424547,"version":"build-2803163510"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1097\/inf.0000000000000968","type":"journal-article","created":{"date-parts":[[2015,11,7]],"date-time":"2015-11-07T10:46:29Z","timestamp":1446893189000},"page":"e35-e47","source":"Crossref","is-referenced-by-count":5,"title":["Assessment of Prime-boost Vaccination Using an AS03B-adjuvanted Influenza A (H5N1) Vaccine"],"prefix":"10.1097","volume":"35","author":[{"given":"Patricia","family":"Izurieta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercy Jeane","family":"Uy-Aragon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamadou","family":"Dram\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Vaughn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R3-19-20210202","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1586\/erv.10.141","article-title":"Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine.","volume":"9","author":"Walker","year":"2010","journal-title":"Expert Rev Vaccines"},{"key":"R7-19-20210202","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1086\/652701","article-title":"Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase \u00bd trial in adults.","volume":"201","author":"Langley","year":"2010","journal-title":"J Infect Dis"},{"key":"R8-19-20210202","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S0140-6736(07)61297-5","article-title":"Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.","volume":"370","author":"Leroux-Roels","year":"2007","journal-title":"Lancet"},{"key":"R9-19-20210202","doi-asserted-by":"crossref","first-page":"7428","DOI":"10.1016\/j.vaccine.2009.07.102","article-title":"H5N1 Flu Study Group for Hong Kong, Singapore, Taiwan and Thailand. Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults.","volume":"27","author":"Chu","year":"2009","journal-title":"Vaccine"},{"key":"R10-19-20210202","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1093\/infdis\/jir172","article-title":"Dose-sparing H5N1 AIndonesia052005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study.","volume":"203","author":"Langley","year":"2011","journal-title":"J Infect Dis"},{"key":"R11-19-20210202","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1097\/INF.0b013e3181daf921","article-title":"Immunogenicity and Safety of H5N1 AVietnam11942004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study.","volume":"29","author":"Diez-Domingo","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"R12-19-20210202","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1111\/j.1750-2659.2012.00344.x","article-title":"Transmission dynamics and risk factors for pandemic H1N1-related illness: outbreak investigation in a rural community of British Columbia, Canada.","volume":"6","author":"Janjua","year":"2012","journal-title":"Influenza Other Respir Viruses"},{"key":"R13-19-20210202","first-page":"684","article-title":"Risk factors of influenza transmission in households.","volume":"54","author":"Viboud","year":"2004","journal-title":"Br J Gen Pract"},{"key":"R14-19-20210202","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.virusres.2004.02.029","article-title":"Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use.","volume":"103","author":"Hehme","year":"2004","journal-title":"Virus Res"},{"key":"R16-19-20210202","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1128\/JCM.37.4.937-943.1999","article-title":"Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays.","volume":"37","author":"Rowe","year":"1999","journal-title":"J Clin Microbiol"},{"key":"R17-19-20210202","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.virusres.2004.02.019","article-title":"Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza ADuckSingapore97 vaccine.","volume":"103","author":"Stephenson","year":"2004","journal-title":"Virus Res"},{"key":"R18-19-20210202","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.virusres.2004.02.025","article-title":"Immunogenicity and protective efficacy of influenza vaccination.","volume":"103","author":"Hannoun","year":"2004","journal-title":"Virus Res"},{"key":"R19-19-20210202","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/0264-410X(89)90150-3","article-title":"Antibody induction by influenza vaccines in the elderly: a review of the literature.","volume":"7","author":"Beyer","year":"1989","journal-title":"Vaccine"},{"key":"R21-19-20210202","doi-asserted-by":"crossref","first-page":"5557","DOI":"10.1016\/j.vaccine.2012.06.028","article-title":"Efficacy of an AS03A-adjuvanted split H5N1 influenza vaccine against an antigenically distinct low pathogenic H5N1 virus in pigs.","volume":"30","author":"De Vleeschauwer","year":"2012","journal-title":"Vaccine"},{"key":"R22-19-20210202","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1750-2659.2012.00349.x","article-title":"An assessment of prime-boost vaccination schedules with AS03A-adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults.","volume":"7","author":"Gillard","year":"2013","journal-title":"Influenza Other Respir Viruses"},{"key":"R24-19-20210202","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.vaccine.2009.10.017","article-title":"Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.","volume":"28","author":"Leroux-Roels","year":"2010","journal-title":"Vaccine"},{"key":"R25-19-20210202","doi-asserted-by":"crossref","first-page":"6408","DOI":"10.1016\/j.vaccine.2011.04.072","article-title":"Immunological priming induced by a two-dose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of AS03 adjuvant in adults: results of a randomised single heterologous booster dose study at 15 months.","volume":"29","author":"Risi","year":"2011","journal-title":"Vaccine"},{"key":"R26-19-20210202","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1093\/infdis\/jiu359","article-title":"Heterologous prime-boost vaccination using an AS03B-adjuvanted influenza A(H5N1) vaccine in infants and children3 years of age.","volume":"210","author":"Nolan","year":"2014","journal-title":"J Infect Dis"},{"key":"R27-19-20210202","doi-asserted-by":"crossref","first-page":"792","DOI":"10.4161\/hv.6.10.12915","article-title":"Pre-pandemic and pandemic influenza vaccines.","volume":"6","author":"Rockman","year":"2010","journal-title":"Hum Vaccin"},{"key":"R28-19-20210202","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/1471-2334-14-266","article-title":"A model-based economic analysis of pre-pandemic influenza vaccination cost-effectiveness.","volume":"14","author":"Halder","year":"2014","journal-title":"BMC Infect Dis"},{"key":"R29-19-20210202","doi-asserted-by":"crossref","first-page":"5837","DOI":"10.1016\/j.vaccine.2010.06.065","article-title":"Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months.","volume":"28","author":"Carmona","year":"2010","journal-title":"Vaccine"},{"key":"R30-19-20210202","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1016\/j.vaccine.2011.04.011","article-title":"Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents.","volume":"29","author":"Garcia-Sicilia","year":"2011","journal-title":"Vaccine"},{"key":"R31-19-20210202","doi-asserted-by":"crossref","first-page":"c2649","DOI":"10.1136\/bmj.c2649","article-title":"Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study.","volume":"340","author":"Waddington","year":"2010","journal-title":"BMJ"},{"key":"R32-19-20210202","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/infdis\/jiu548","article-title":"AS03B-adjuvanted H5N1 influenza vaccine in children 6 months through 17 years of age: a phase IIIII randomized, placebo-controlled, observer-blind trial.","volume":"211","author":"Kosalaraksa","year":"2015","journal-title":"J Infect Dis"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000000968","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:09:09Z","timestamp":1620954549000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201602000-00019"}},"subtitle":["A Randomized Trial in Children of Three to Less Than Eighteen Years of Age"],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000000968","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]}}}